[Topical carbonic anhydrase inhibitors in the treatment of glaucoma].
Systemically administered carbonic anhydrase inhibitors have been in clinical use since the 1950's. Their use and side effects have been reviewed extensively. Our review summarizes the development of topically administered carbonic anhydrase inhibitors in patients with glaucoma. Moreover, it documents clinical trials leading to the present choice of dorzolamide (MK-507), which is now being reviewed for worldwide approval for marketing by 1995.
Bayer
A
A
Department of Ophthalmology, Mount Sinai Medical Center, New York City, USA.
Ferrari
F
F
Maren
T H
TH
Erb
C
C
D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D009883:Ophthalmic Solutions; D013449:Sulfonamides / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use
D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide
Inhibiteurs locaux de l'anhydrase carbonique dans le traitement du glaucome.